Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaires George Soros and James Dinan Love These Stocks

Page 1 of 2

Recently, we have gone through our database consisting of over 700 hedge funds and found that Dow Chemical Co (NYSE:DOW), Zoetis Inc (NYSE:ZTS), Allergan PLC (NYSE:AGN), Endo International plc (NASDAQ:ENDP) and DISH Network Corp (NASDAQ:DISHdrew the attention of prominent billionaire investors George Soros and James Dinan, both of whom disclosed long positions in these companies as of the end of March. So, let’s take a closer look at how these stocks are positioned in the billionaires’ portfolios and how they have performed over the last few months.

hedge fund research

George Soros, or ‘the man who broke the bank of England’, is an 84-year-old billionaire famously known for his bets against the British Pound, which made him a fortune. Now he holds the 29th position on the Forbes list of the wealthiest people on the planet, with a net worth of $24.2 billion. Over the last year, his family office, Soros Fund Management, returned about 8% versus the 3.3% industry average during this time, according to Hedge Fund Research. James Dinan’s figures are a bit more modest, relatively speaking. He ranks 276th in the Forbes’ US billionaires list, with a net worth of $2.4 billion. According his the latest 13F filing, the equity portfolio of his fund, York Capital Management, was valued at $14.56 billion. The fund is widely diversified across all sectors, with the consumer staples and finance industries leading the way in terms of capital allocation.

George Soros
George Soros
Soros Fund Management

During the first three months of the year, Soros trimmed his holding in Dow Chemical Co (NYSE:DOW), a $61.43 billion basic materials company, by 11% to 4.36 million shares valued at $222.12 million. This company is one of the largest manufacturers of integrated materials in the world, and is now undergoing a transformation of its business, reorganizing and restructuring its divisions, with the goal of increasing its return on capital. Some analysts believe that the stock is trading with a decent 20% margin of safety. Dinan’s York Capital Management held about 4.68 million shares of Dow Chemical Co (NYSE:DOW), valued at $227.73 million at the end of the first quarter.

Soros’ position in Zoetis Inc (NYSE:ZTS) contains 4.11 million shares, worth $190.10 million. So far this year, the stock of the developer of animal vaccines has advanced by 11.62%. Zoetis Inc (NYSE:ZTS), a former animal health division of Pfizer Inc (NYSE:PFE), was saddled with $3.6 billion of debt from its parent company after its spin-off in 2013. Despite that, Zoetis Inc (NYSE:ZTS) has very nice perspectives, since it operates in a relatively uncompetitive segment, with lucrative 10-12% profit margins. The stock has experienced an eventful ride in the last week, as it was rumored that Valeant would pursue a purchase of the company, which we hinted could be a possibility in March after Bill Ackman took a big stake in Valeant. However, the rumors were quickly shot down, leading to a surge last Thursday, followed by a crash back down last Friday. BMO also downgraded the stock to ‘Market Perform’ last Friday, though it raised its price target to $57 from $51 at the same time. James Dinan’s York Capital Management held about 4.48 million shares of Zoetis valued at $207.29 million at the end of March.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!